MA45840A - Comprimé multicouche de mazindol à libération immédiate/libération prolongée pour le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah) - Google Patents

Comprimé multicouche de mazindol à libération immédiate/libération prolongée pour le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah)

Info

Publication number
MA45840A
MA45840A MA045840A MA45840A MA45840A MA 45840 A MA45840 A MA 45840A MA 045840 A MA045840 A MA 045840A MA 45840 A MA45840 A MA 45840A MA 45840 A MA45840 A MA 45840A
Authority
MA
Morocco
Prior art keywords
mazindol
adhd
treatment
attention deficit
hyperactivity disorder
Prior art date
Application number
MA045840A
Other languages
English (en)
Inventor
Lewis P Amsel
Scott Brantley
Virginia Schmith
Alexander C Zwyer
Original Assignee
Nls Pharmaceutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2016/055048 external-priority patent/WO2017152974A1/fr
Application filed by Nls Pharmaceutics Ag filed Critical Nls Pharmaceutics Ag
Publication of MA45840A publication Critical patent/MA45840A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA045840A 2016-03-09 2017-03-08 Comprimé multicouche de mazindol à libération immédiate/libération prolongée pour le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah) MA45840A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662305600P 2016-03-09 2016-03-09
PCT/EP2016/055048 WO2017152974A1 (fr) 2016-03-09 2016-03-09 Comprimé multicouche de mazindol à libération immédiate/libération prolongée pour le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah)

Publications (1)

Publication Number Publication Date
MA45840A true MA45840A (fr) 2021-05-05

Family

ID=58710015

Family Applications (2)

Application Number Title Priority Date Filing Date
MA055045A MA55045A (fr) 2016-03-09 2017-03-08 Comprimé multicouche de mazindol à libération immédiate/libération prolongée pour le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah)
MA045840A MA45840A (fr) 2016-03-09 2017-03-08 Comprimé multicouche de mazindol à libération immédiate/libération prolongée pour le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA055045A MA55045A (fr) 2016-03-09 2017-03-08 Comprimé multicouche de mazindol à libération immédiate/libération prolongée pour le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah)

Country Status (16)

Country Link
US (3) US11207271B2 (fr)
EP (2) EP3426232B1 (fr)
JP (1) JP7127832B2 (fr)
KR (1) KR102304743B1 (fr)
CN (2) CN116803379A (fr)
AU (2) AU2017230974B2 (fr)
BR (1) BR112018068143A2 (fr)
CA (1) CA3016852C (fr)
ES (1) ES2884973T3 (fr)
IL (2) IL295519A (fr)
MA (2) MA55045A (fr)
MX (1) MX2018010864A (fr)
NZ (1) NZ745921A (fr)
PL (1) PL3426232T3 (fr)
PT (1) PT3426232T (fr)
WO (1) WO2017153846A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016192680A1 (fr) 2015-06-03 2016-12-08 Triastek, Inc. Formes galéniques et leur utilisation
WO2019058172A1 (fr) 2017-09-07 2019-03-28 Nls-1 Pharma Ag Traitement au mazindole pour une dépendance à l'héroïne et un trouble lié à l'utilisation de substances psychoactives
WO2019137200A1 (fr) * 2018-01-09 2019-07-18 Triastek, Inc. Formes posologiques pour médicament à usage oral comprenant une dose fixe de non-stimulant du tdah et de stimulant du tdah
CN110946826B (zh) * 2019-12-12 2022-02-22 烟台大学 一种利奥西呱口服制剂及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855440A (en) 1988-02-16 1989-08-08 Sherex Chemical Company, Inc. Method for producing stabilized imidazoline derivatives
US20060240105A1 (en) 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
JP2001102172A (ja) 1999-09-30 2001-04-13 Idemitsu Kosan Co Ltd 有機エレクトロルミネッセンス素子
GB0009522D0 (en) 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
JP2004520275A (ja) 2000-11-10 2004-07-08 エフ．ホフマン−ラ　ロシュ　アーゲー 加水分解的に不安定な組成物
CN1579401A (zh) * 2003-08-11 2005-02-16 李亦武 一种止咳平喘药物新剂型及制备方法
US20050226927A1 (en) * 2004-04-02 2005-10-13 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
CN1593404A (zh) * 2004-07-16 2005-03-16 南京亿华药业有限公司 甲硝唑双层叠合缓释片及其制备方法
WO2006069030A1 (fr) * 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Compositions pharmaceutiques destinees a des troubles du sommeil
AR057946A1 (es) * 2005-11-28 2007-12-26 Orexigen Therapeutics Inc Formulacion de zonisamida de liberacion sostenidda
KR100752417B1 (ko) 2006-02-14 2007-08-28 대원제약주식회사 안정성이 증진된, 마진돌을 포함하는 약제학적 조성물
FR2899476B1 (fr) 2006-04-11 2008-07-04 Assist Publ Hopitaux De Paris Association du mazindol dans le traitement du deficit de l'attention/hyperactivite
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
CN1985823A (zh) * 2006-11-21 2007-06-27 北京润德康医药技术有限公司 一种含有盐酸二甲双胍罗格列酮的缓释制剂及其制备方法
CA3066426A1 (fr) * 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Compositions pharmaceutiques renfermant un antiemetique et un analgesique opioide
US20090318520A1 (en) * 2008-06-20 2009-12-24 Afecta Pharmaceuticals Drive Use of isoindoles for the treatment of neurobehavioral disorders
WO2011123496A1 (fr) * 2010-03-31 2011-10-06 Supernus Pharmaceuticals, Inc. Formulations de mazindol
US8796338B2 (en) * 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders

Also Published As

Publication number Publication date
JP2022160647A (ja) 2022-10-19
MX2018010864A (es) 2019-03-28
CN116803379A (zh) 2023-09-26
US20220160639A1 (en) 2022-05-26
IL261418B (en) 2022-09-01
CA3016852C (fr) 2021-03-23
KR102304743B1 (ko) 2021-09-24
IL261418A (en) 2018-10-31
IL295519A (en) 2022-10-01
NZ745921A (en) 2021-12-24
WO2017153846A3 (fr) 2017-10-12
US20210038521A1 (en) 2021-02-11
EP3928770A1 (fr) 2021-12-29
EP3426232A2 (fr) 2019-01-16
WO2017153846A2 (fr) 2017-09-14
AU2017230974A1 (en) 2018-09-20
CN109152740A (zh) 2019-01-04
JP2019507771A (ja) 2019-03-22
JP7127832B2 (ja) 2022-08-30
BR112018068143A2 (pt) 2019-07-30
PT3426232T (pt) 2021-08-31
EP3426232B1 (fr) 2021-06-02
ES2884973T3 (es) 2021-12-13
US11207271B2 (en) 2021-12-28
KR20190019044A (ko) 2019-02-26
MA55045A (fr) 2021-12-29
US20240165034A1 (en) 2024-05-23
CA3016852A1 (fr) 2017-09-14
AU2022202771A1 (en) 2022-05-19
AU2017230974B2 (en) 2022-02-03
PL3426232T3 (pl) 2022-01-10

Similar Documents

Publication Publication Date Title
MA49144A (fr) Polythérapies pour le traitement du cancer
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MA45192A (fr) Traitement d'association
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA45037A (fr) Polythérapie à base d'arnm pour le traitement du cancer
MA47719A (fr) Esketamine pour le traitement de la dépression
MA41449A (fr) Polythérapies pour le traitement de cancers
MA48637A (fr) Polythérapies pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
MA54925A (fr) Compositions pour le traitement de troubles acido-basiques
MA45429A (fr) Polythérapie pour le traitement du cancer
MA45840A (fr) Comprimé multicouche de mazindol à libération immédiate/libération prolongée pour le traitement du trouble déficitaire de l'attention avec hyperactivité (tdah)
MA41052A (fr) Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA42999A (fr) Polythérapie pour le traitement de malignités
MA41555A (fr) Polythérapie pour le traitement du cancer
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
MA47776A (fr) Polythérapies pour le traitement du cancer du sein
MA45574A (fr) Procédés de traitement de lésions ou de pathologies liées à un dème du snc
MA45492A (fr) Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène
MA43051A (fr) Polythérapie pour le traitement d'une du vhc
MA43431A (fr) Procédé d'aide à l'évaluation du pronostic du cancer du sein et appareil d'aide à l'évaluation du pronostic du cancer du sein
MA41136A (fr) Composés pour le traitement d'un cancer
CN302570521S (zh) 水池龙头花洒
CN302309995S (zh) 洗盆